Every year, over 1,000 people in the UK die from asthma attacks, most of which are triggered by the common cold virus (rhinovirus). Existing treatments cannot prevent these attacks, and patients urgently need a preventative therapy. This project tests a drug called OC459, which blocks the receptor for a molecule called prostaglandin D2 (PGD2). Previous work by the researchers showed that rhinovirus infection ramps up PGD2-driven inflammation in the airways during an asthma attack, and that the severity of the attack correlates with this inflammation. By blocking PGD2 with OC459, the team aims to stop the dangerous chest symptoms and limit the infection to a runny nose and sore throat, as it would be in a non-asthmatic person. The study will involve 28 asthmatics who are deliberately infected with rhinovirus under controlled conditions. Half will receive OC459, half a placebo. This experimental model is far cheaper and faster than the alternative—recruiting hundreds of patients and waiting for natural attacks, which costs over £30 million. If OC459 works, it could become the first effective preventative treatment for virus-induced asthma attacks, dramatically reducing hospitalisations and deaths.
View original technical description
Asthma attacks are responsible for over 1000 deaths a year in the UK alone and are the main cause for hospitalisation for suffers of asthma. The most common trigger for asthma attacks is the common cold virus (rhinovirus). Currently available therapies fail to prevent virus-induced asthma attacks and asthmatic patients desperately need an effective, preventative treatment for this. In light of the recognised relationship between rhinovirus and asthma attacks, an experimental model has been developed to study this association more closely. This involves inoculating asthmatics with rhinovirus via a spray in the nose under controlled conditions and allows the study of novel therapies. Due to careful selection of asthmatics without severe disease or a history of hospitalisation due to virus infections we have successfully used this model in over 50 asthmatics in a number of studies with great success. Unfortunately the only alternative option for studying asthma attacks (and the effect of therapies on them) is to recruit several hundred asthmatics and wait for asthma attacks to occur naturally. Such studies cost in excess of £30 million to conduct given the length of the study and the number of patients needed for recruitment (in order to capture enough attacks). The human experimental rhinovirus infection model therefore allows the study of asthma attacks and any treatment effects in a short amount of time and at a fraction of the cost. A molecule known as prostaglandin D2 (PGD2 )has been shown to be a very important link in the pathway of inflammation known as 'type 2 immunity'. This pathway underlies many of the symptoms that asthmatics develop including breathlessness, cough, chest tightness and wheeze and has been shown to be particularly high in severe asthmatics. We have shown in a recent study using the human rhinovirus model that this type of inflammation (including prostaglandin D2) is increased by rhinovirus in the airway during the virus-induced asthma attack and correlates strongly with the severity of the attack. Therefore blocking this molecule should halt the type 2 inflammation caused by the virus infection and limit the consequences of infection to simply a runny nose and a sore throat (as per non-asthmatic individuals) rather than the potentially life-threatening chest symptoms seen in asthma. Fortunately several drug companies have already developed a drug that blocks the prostaglandin D2 receptor known as 'CRTH2' but none have taken the step to study its effect in preventing asthma exacerbations. Importantly, these drugs have already been trialled in a number of short studies involving several hundred asthmatics and shown to have an excellent safety profile. Additionally these studies have highlighted this type of therapy as very good at suppressing the asthmatic airway inflammation downstream of PGD2. Based on our own research findings of a rhinovirus-induced increase in PGD2, we wish to assess the effect of blocking PGD2 using the CRTH2 receptor blocker 'OC459' in the context of a controlled rhinovirus-induced asthma attack. We have established that a study numbering 28 asthmatics, randomly assigned to either the drug or placebo would be sufficient to identify any benefit of this therapeutic approach to asthma care.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know